Chokri Ben Lamine: Five-year follow-up of KEYNOTE-087
Chokri Ben Lamine, Adult Hematology, Stem Cell Transplantation and Cellular Therapy Assistant Consultant at King Faisal Specialist Hospital and Research Center shared a post on X:
“Five-year follow-up of KEYNOTE-087: Pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma (cHL).
Study overview:
•Anti–PD-1 checkpoint inhibitor pembrolizumab was evaluated across 3 cohorts of patients with R/R cHL:
- Progression after ASCT and subsequent BV therapy (n=69).
- Progression after salvage chemotherapy and BV without ASCT (n=81).
- Progression after ASCT without BV (n=60).
- Median follow-up: 63.7 months.
Key results:
•Duration of response (DOR):
CR (n=58): Not reached (95% CI: 16.1-NR).
PR (n=92): Median 11.3 months (95% CI: 8.2-16.8).
•Progression-Free Survival (PFS):
CR: Median 55.6 months (95% CI: 21.7-NR).
PR: Median 13.8 months (95% CI: 7.2-21.2).
PD: Median 2.8 months (95% CI: 2.7-2.8).
Conclusion: Pembrolizumab demonstrated durable responses and significant PFS in subsets of R/R cHL patients.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023